EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease

Sukirthini Balendran-Braun iD, Ursula Vinatzer, Sandra Liebmann-Reindl, Manuela Lux, Petra Oliva iD, Stefaan Sansen, Thomas Mechtler, David C Kasper iD, Berthold Streubel

Human Mutation · 2024

DOI: 10.1155/2024/6248437 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Mutation, 2024. Verfasst von Sukirthini Balendran-Braun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type II, alpha-Glucosidases, Genetic Testing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi Genzyme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pompe disease (PD) is a rare autosomal recessive lysosomal disorder caused by loss‐of‐function of the α ‐glucosidase ( GAA ) gene. The deficient GAA enzyme activity may result in potential life‐threatening muscle weakness, thus requiring a rapid diagnosis to initiate therapeutic interventions. In this large retrospective study, we analyzed 30.836 PD suspect samples from 57 countries using a two‐step approach utilizing dried blood spots (DBSs): biochemical testing of GAA activity followed by complementary genetic sequencing of GAA in biochemically conspicuous cases. Of these 30.836 samples, 2% ( n = 639) were excluded; accordingly, this study consisted of 30.193 cases. Biochemical testing of GAA enzyme activity showed normal values in 28.354 (93.90%) and enzyme activity below the cut‐off in 1843 (6.10%) cases. These biochemically suspicious cases were genetically analyzed. We identified 723 Pompe cases with 283 different GAA alterations, and 98 variants have been unpublished so far. The most common variant was the splice variant c.‐32‐13T>G (IVS1). Looking at the IVS1‐genotype, the majority was compound heterozygous ( n = 169) and identified in late‐onset cases ( n = 162). Comparison of early‐ versus late‐onset cases to evaluate whether certain genotypes correlate with the age of onset revealed that homozygosity was predominantly found in infantile (85.65%) and compound heterozygosity in late‐onset (76.9%) cases. Analysis of homozygous cases revealed 61% nonsense variants in the early stages and 87% missense variants in the late stages. Mapping of disease‐associated (homozygous) missense variants to functional GAA protein domains showed that missense variants were found throughout GAA, but we identified enrichment in the catalytic domain. A strict genotype–phenotype correlation cannot be established; nevertheless, a phenotypic implication of some GAA variants could be drawn (e.g., c.896T>C/p.L299P, c.2015G>A/p.R672Q, and c.‐32‐13T>G). The combined enzyme activity and genetic testing from DBS cards can reliably identify PD and significantly accelerate diagnosis. We identified new genetic variants that contribute to the spectrum of pathogenic variants of the GAA gene.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Storage Disease Type IIalpha-GlucosidasesGenetic TestingHumansMaleFemaleRetrospective StudiesChildAdultChild, PreschoolInfantAdolescentGenotypeMutationYoung AdultMiddle Aged

Stichwörter der Autor:innen

GAA variantsPompe diseasedried blood spots (DBSs)genotype–phenotypeα-glucosidase (GAA) enzyme

Substanzen

alpha-GlucosidasesGAA protein, human

Autor:innen und Institutionen

  • Department of Pathology, Medical University of Vienna, Vienna, Austria.
  • ARCHIMED Life Science GmbH, Vienna, Austria.
  • Sanofi Genzyme, Amsterdam, Netherlands.

ORCID-Profile: Sukirthini Balendran-Braun, Petra Oliva, David C Kasper

Förderung

  • Sanofi Genzyme

Zitieren

APA

Balendran-Braun, S., Vinatzer, U., Liebmann-Reindl, S., Lux, M., Oliva, P., Sansen, S., Mechtler, T., Kasper, D. C., & Streubel, B. (2024). Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease. Human Mutation. https://doi.org/10.1155/2024/6248437

Vancouver

Balendran-Braun S, Vinatzer U, Liebmann-Reindl S, Lux M, Oliva P, Sansen S, et al. Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease. Human Mutation. 2024. doi:10.1155/2024/6248437

BibTeX
@article{BalendranBraun2024,
  author = {Balendran-Braun, Sukirthini and Vinatzer, Ursula and Liebmann-Reindl, Sandra and Lux, Manuela and Oliva, Petra and Sansen, Stefaan and Mechtler, Thomas and Kasper, David C and Streubel, Berthold},
  title = {Biochemical and Genetic Testing of GAA in Over 30.000 Symptomatic Patients Suspected to Be Affected With Pompe Disease},
  journal = {Human Mutation},
  year = {2024},
  doi = {10.1155/2024/6248437}
}
Kostenlos starten →